Application of IL-13R?2-directed Toxin Fusion Protein in Tumor Therapy
- VernacularTitle:IL-13R?2介导的毒素融合蛋白在肿瘤治疗中的应用
- Author:
Juan DU
;
Hong-Gang HU
;
Ling-Ling HOU
;
- Publication Type:Journal Article
- Keywords:
Carcinoma IL-13R?2 Toxin fusion protein Tumor therapy
- From:
China Biotechnology
2006;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
The research of interleukin-13 receptor ?2(IL-13R?2) chain is a rising pop these years.Previous studies have shown that many human tumors overexpress IL-13R?2 chain,while normal cells do not express this receptor or express very low level.This difference of express level is significant to diagnose and cure tumors by the IL-13R?2-directed toxin fusion protein.During the past decade,the structure and the function of IL-13R?2 together with the relationship between this receptor and tumors has been further developed.Therefore new therapies and theories can be proposed as the clinical tumor treatments.In this case,the expression in various tumor cell lines was not only focused on but also on the IL-13 and toxin fusion protein killing effect in both the cell level and the in vivo level.Besides,an overview of the mechanism in the treatment of IL-13R?2-directed toxin fusion protein together with the improved methods for fusion protein purification and other relative tumor therapy was given.In conclusion,the current status and progress of IL-13R?2 as well as IL-13R?2-directed toxin fusion protein in tumor therapy were represented.
